WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the creation of its new Scientific Advisory Board (SAB), marking a strategic step in advancing its focus on immuno-inflammatory diseases. The board’s initial members include distinguished pulmonology experts Dr. Marianne Mann and Dr. Zuzana Diamant, whose collective expertise spans regulatory science, clinical research, and drug development.
“We are delighted to welcome these distinguished scientists and clinicians to our Scientific Advisory Board,” said Dr. Neal Walker, Interim CEO and Chair of the Board of Directors of Aclaris Therapeutics. “Their expertise in respiratory medicine and drug development will be important in guiding our development programs as we work to advance novel therapeutics for patients with immuno-inflammatory diseases. Each initial member brings unique and complementary experience spanning regulatory science, clinical development, and translational research that will help guide our development programs.”
Dr. Mann brings over 30 years of experience in regulatory science and clinical care. Her roles at the FDA included Deputy Director of the Division of Pulmonary and Allergy Drug Products, where she evaluated clinical protocols for respiratory and allergic conditions. She also held leadership positions at the National Institutes of Health, overseeing respiratory disease research. Her proficiency in trial design and regulatory strategy adds depth to the SAB’s capabilities.
Dr. Diamant, a guest professor at KU Leuven in Belgium and an internationally recognized expert in respiratory medicine, brings extensive knowledge of asthma, COPD, and allergy research. Having co-authored over 200 peer-reviewed publications, she provides critical expertise in clinical asthma models, biomarkers, and targeted drug interventions. Her leadership in global task forces on chronic inflammatory respiratory diseases further underscores her influence in the field.
Aclaris Therapeutics’ formation of the SAB underscores its commitment to advancing innovative therapies for patients with unmet medical needs in immuno-inflammatory conditions. The combined experience of Dr. Mann and Dr. Diamant aims to strengthen the company’s development efforts, industry impact, and scientific direction.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.